山東路橋(000498.SZ):路橋集團17.11%股權已變更登記至公司名下
格隆匯 9 月 25日丨山東路橋(000498.SZ)公佈,公司收到中國證監會核准文件後及時開展了標的資產過户相關工作。截至公告日,此次發行股份購買資產並募集配套資金暨關聯交易之標的資產山東省路橋集團有限公司(“路橋集團”)17.11%股權已完成過户。
2020年9月23日,路橋集團17.11%股權已變更登記至公司名下,路橋集團取得了濟南市槐蔭區行政審批服務局換髮的營業執照(統一社會信用代碼:91370000163048885W)。此次變更完成後,公司持有路橋集團100%股權,路橋集團成為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.